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Abstract 
Cancer risk is an important concern for International Space Station (ISS) missions and future 
exploration missions to Mars and other destinations. As space programs mature, an important 
question arises as to the likelihood of a causal association between a crew members’ radiation 
exposure and the occurrence of cancer. The probability of causation (PC), also denoted as 
attributable risk, is used to make such an estimate. PC estimates above 50% suggest an 
observed cancer was more likely to be attributed to radiation exposure than not. Because of the 
uncertainties in estimating radiation cancer risks, analysis of terrestrial occupational exposure 
risk has estimated PC at the 95th or 99th percentile confidence level (CL) in assessing the 
possible relationship between prior radiation exposures and cancer. In this report, we first 
summarize the NASA model of space radiation cancer risks and uncertainties, including 
improvements to represent uncertainties in tissue-specific cancer incidence models for never-
smokers (NS) and the U.S. average population. We then report on tissue-specific cancer 
incidence estimates and PC for different post-mission times for ISS and exploration missions. 
Results show that leukemia and stomach cancer are most likely related to space radiation 
exposures followed by lung, colon, bladder, and liver cancers. PC estimates for a single ISS 
mission are not found to exceed 50% even at the 95% CL. However, median PC and 95% CL  
are found to exceed 50% for many cancer types for deep space missions. PC estimates for NS 
are estimated to be increased compared to a U.S. average population for lung and several other 
tissues, although absolute risks are reduced for NS compared to the U.S. average population. 
An important conclusion from our analysis is that the NASA policy to limit the risk of exposure-
induced death to 3% at the 95% CL largely ensures that estimates of the PC for most cancer 
types would not reach a level of significance. Reducing uncertainties through radiobiological 
research remains the most efficient method to extend mission length and establish effective 
mitigators for cancer risks. Efforts to establish biomarkers of space radiation-induced tumors 
and to estimate PC for rarer tumor types are briefly discussed.
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1. Introduction 
In this paper, we discuss methods to estimate the probability of causation (PC), also known as 
Attributable Risk (AR), for space radiation exposures. Astronauts are exposed to galactic cosmic 
rays (GCR)—made up of high-energy protons and high-energy and charge (HZE) nuclei, and 
solar particle events (SPEs)—comprised largely of low- to medium-energy protons, which are a 
critical challenge for space exploration. Experimental studies have shown that HZE nuclei produce 
both qualitative and quantitative differences in biological effects compared to terrestrial radiation 
(reviewed in NAS, 1996; Cucinotta and Durante, 2006; Durante and Cucinotta, 2008; 
Schimmerling et al., 1999; NCRP, 2006) leading to large uncertainties in predicting exposure 
health outcomes to humans. The uncertainties in estimating GCR health risks are a major 
limitation to the length of space missions and the evaluation of potential risk mitigators. NASA 
limits astronaut exposures to a 3% risk of exposure-induced death (REID), and protects against 
uncertainties in risks projections using an assessment of 95% confidence intervals (CIs) of risk 
estimates (Cucinotta et al., 2011). Beyond efforts related to risk limitation prior to a mission, there 
will also be a concern for cancers observed in crew members at post-mission and their possible 
association with prior space radiation exposures. The PC is a conditional probability of risk used 
as an indicator of a potential causal relationship between radiation exposure and occurrence of 
cancer in a population. The calculation of PC with concomitant uncertainty analysis will allow 
NASA to make estimates that an observed cancer was caused by occupational exposure; 
however, the estimates should be augmented with considerations of an individual’s family history 
of disease, possible  exposure to other carcinogens, and of individual based biomarkers.  
Astronauts and other healthy workers enjoy many lifestyle factors that lead to reduced lifetime 
cancer risks compared to the U.S. average population (Calle et al., 1999). Healthy worker 
attributes found for astronauts include optimal ranges of body mass index (BMI), moderate alcohol 
use, excellent nutrition and exercise regimes, and health care (LSAH 2003). More importantly, 
more than 90% of astronauts are never-smokers (NS) and therefore are expected to have lower 
background cancer rates than the U.S. average rates, which include current and former smokers 
along with NS. It is well known that NS have lower rates of cancer, circulatory and pulmonary 
diseases, and longer lifespan than former or current smokers (Thun et al., 1995; Doll et al., 2004). 
Indeed, more than 20% of all deaths in the U.S. are associated with tobacco exposure, including 
over 80% of all lung cancer deaths (CDC 2010). In addition, epidemiology studies suggest a 
harmful synergistic interaction between radiation and tobacco exposure occurs (Gilbert et al., 
2003; Furukawa et al., 2010; Leuraud et al., 2011; Cucinotta et al., 2012). Exposure to second-
hand smoke would be variable in the astronaut or other healthy populations, and can significantly 
increase lung cancer and circulatory disease risk (CDC 2010). Radiation risk estimates have used 
models based on the U.S. average population (NCRP, 2000) until recently (Cucinotta and 
Chappell, 2011). Because cancer risk estimates are made using a mixture of multiplicative and 
additive risk transfer models, the lower background cancer rates of a healthy population reduce 
radiation risk estimates compared to estimates for the U.S. average population (Cucinotta et al. 
2011, 2012). In this report, we show that the opposite effect will occur for the conditional 
probability represented by the PC, whereby the PC is increased for several radiogenic cancers for 
a NS population compared to the U.S. average population.  
 2 
 
Evidence that astronauts should be considered to be at lower risk for cancers and enjoy longer 
lifespan compared to the U.S. average population is borne out by analysis of Kaplan-Meir survival 
curves (Figure 1) and Standard Mortality Ratios (SMR) (Table 1), where the cohort of NASA 
astronauts and payload specialists is compared to the U.S. average population (CDC MMWR 
2008) and the estimates for a NS population. These comparisons include results after censoring 
18 of 19 occupationally related accidental deaths from space missions or training considered 
atypical of U.S. workers. The largely male cohort of astronauts and payload specialists show a 
longer longevity and reduced SMR  in comparison to the U.S. average population, and are more 
similar to a population of female NS, which is a strong indication that a healthy worker effect 
occurs for astronauts. The population effective dose (over 90 Sv for the astronaut cohort 
[Cucinotta,  2001; Cucinotta et al., 2008] ) is unlikely to have led to any increase in cancers at this 
time. We next discuss the NASA 2010 cancer risk assessment model (Cucinotta et al., 2011) and 
its application to PC estimates for International Space Station (ISS) and exploration missions. In 
the past, uncertainty analyses of PC estimates have been used to screen exposed persons for a 
potential causal relationship to an observed cancer, and in the determination of monetary 
compensation (NIH 2003; DHHS 2002). We describe point estimates and upper 95% confidence 
levels (CL) of the PC for 15 radiogenic tissue sites and a grouped ―remainder‖ category 
representing other cancer sites. Predictions for missions to the ISS, near Earth asteroids (NEAs), 
and Mars are described, including comparisons for different ages of exposure and disease 
diagnosis.  
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Figure 1. Kaplan-Meier survival versus age for astronauts and payload specialists compared to U.S. males and 
our projections for NS males. The left panel includes occupational deaths related to flight accidents or training, 
and right panel censors occupational deaths. Data from the Astronaut Fact Book (NASA 2005) and 
http://www.jsc.nasa.gov/Bios/. 
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Table 1a. Statistics for Fatalities Among Astronauts and Payload Specialists* 
Category Total Frequency Death Frequency 
Male Astronauts 269 41 
Female Astronauts 40 3 
Total Astronauts 316 43 
Payload Specialist 23 1 
Total 339 44 
*Causes of death were 10 cancers, 4 circulatory diseases, 1 central nervous system, 19 occupational accidental 
deaths, 4 non-occupational accidental deaths, and 5 other causes of death. Data from the Astronaut Fact Book 
(NASA 2005) and http://www.jsc.nasa.gov/Bios/. 
 
 
 
Table 1b. Standard Mortality Ratio (SMR) for Astronauts and Payload Specialists Relative to U.S. Average or NS 
average (gender weighted to proportion of Male and Female astronauts) or Female NS, Suggests Astronauts have 
Lifetime Risks Similar to Female NS 
Comparison SMR P-value 
Astronauts vs. U.S. avg. 0.67 [0.50, 0.90] 0.0006 
Censoring tragedies vs. U.S. avg. 0.40 [0.27, 0.58] <10
-6
 
Astronauts vs. NS avg. 0.88 [0.65, 1.18] 0.391 
Censoring tragedies vs. NS avg. 0.52 [0.35, 0.76] 0.00067 
Astronauts vs. Female NS 1.33 [0.99, 1.78] 0.0592 
Censoring tragedies vs. Female NS 0.78 [0.53, 1.15] 0.215 
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2. Cancer Risk Projection Model 
The instantaneous cancer incidence or mortality rates, I and M, respectively, are modeled as 
functions of dose D, or dose-rate Dr, gender, age at exposure aE, and attained age a or latency L, 
which is the time after exposure L=a-aE. The I (or M ) is a sum over rates for each tissue that 
contributes to risk,  IT . These dependencies vary for each cancer type that could be increased by 
radiation exposure. The total risk of exposure-induced cancer (REIC) is calculated by folding the 
instantaneous radiation cancer incidence rate with the probability of surviving to time t, which is 
given by the survival function S0(t) for the background population times the probability for radiation 
cancer death at previous time, and then integrating over the remainder of a lifetime: 



E
t
E
a
EM
a
Dazdz
EIE etSDaadtDaREIC
),,(
0 )(),,(),()1(

  
where z is the dummy integration variable. After adjustment for low dose and dose-rates though 
the dose and dose-rate effectiveness factor (DDREF) and radiation quality, the tissue-specific, 
cancer incidence rate for an organ dose equivalent, HT , can be written as a weighted average of 
the multiplicative and additive transfer models, often called a mixture model: 
DDREF
H
aaEARvaaaERRvHaa TETTITETTTEIT )],()1()(),([),,()2( 0    
where vT is the tissue-specific transfer model weight, 0IT is the tissue-specific cancer incidence 
rate in the reference population, and where ERRT and EART are the tissue specific excess 
relative risk and excess additive risk per Sievert, respectively. The Hazard rates for cancer 
mortality M are modeled with similar approaches following the BEIR VII report (2006). Tissue  
weights assumed in the NASA 2010 model are shown in Table 2 along with recommendations 
from other reports. In the NASA 2010 Model (Cucinotta and Chappell, 2011; Cucinotta et al., 
2011), we used the United Nations Special Committee on the Effects of Atomic Radiation 
(UNSCEAR) report fitted excess additive risk (EAR) and excess relative risk (ERR) models for 
most tissue sites with the results from Preston et al. (2007) for a few tissues not reported by 
UNSCEAR. UNSCEAR employed Poisson maximum-likelihood methods and Bayesian analysis 
to represent dosimetry errors to fit generalized ERR and EAR models to the Life-Span Study of 
the Japanese atomic-bomb survivors (LSS) for cancer incidence for REIC. The ERR function 
fitted to the LSS data was: 
)]ln()ln()ln(1exp[)(),,,()3( 4321
2
EES
D
E aaaaeDDDLaaERR 
   
with a similar form for the EAR function. A linear dose response model provided the best fits to 
the tissue-specific cancer incidence data for solid cancers. For leukemias, the linear-quadratic 
model provided the best fit. The addition of the latency dependence, L=a-aE,  was significant for 
several tissues, including EAR models for colon, breast, and non-melanoma skin cancer, and 
ERR and EAR functions for the category of all other solid cancer incidence. For breast and 
thyroid cancers, the NASA 2010 models follows BEIR VII, which recommended the use of 
results from a meta-analysis of several exposed cohorts, replacing results from the LSS with 
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additive transfer models used for breast cancer (Preston et al., 2002) and multiplicative transfer 
models used for thyroid cancer (Ron et al., 1995). For estimating cancer risks for low dose or 
dose-rate exposures, NCRP Report 132 (NCRP 2000) used a DDREF of 2. The BEIR VII 
Report, recommended a DDREF of 1.5 based on Bayesian analysis of the LSS data and a 
select group of mouse tumor studies. The NIH uses (NIH 2003) a values close to 1.75, which is 
the choice for the NASA 2010 model (Cucinotta and Chappell, 2011). 
Table 2. Tissue-Specific Transfer Weight T for Multiplicative Risk Transfer. Additive Risk Transfer Weight is then 
Given by 1-T. Values Described on page 126 of NCRP Report No. 132  (2000), and from pages 275-276 of BEIR 
VII (2006).   
Tissue NCRP No. 132 BEIR VII NASA 2010 
Lung 0.5 0.3 0.5 
Breast 0.5 0** 0** 
Thyroid 0.5 1.0** 1.0** 
Stomach,     
Colon, Liver, 
Esophagus 
0.5 0.7 0.7 
Leukemia 0.0 0.7 0.5 
All Others 0.5 0.7 0.5 
**Based on meta-analysis results described in BEIR VII. 
Adjusting U.S. Cancer Rates for Never-Smokers Cancer Estimates 
We estimated gender-specific NS cancer rates to represent a reference population by using 
age-specific rates for lung cancer and relative risk factors derived from literature searches for 
other cancers. Age- and gender-specific NS lung cancer rates were recently compiled by Thun 
et al. (2008) from an analysis of 13 cohorts and 22 cancer registries. These rates are used for 
our analysis of radiation lung cancer risks for NS. For other cancers, we use Center for Disease 
Control (CDC) estimates of proportions of cancer deaths for smokers (S) and former smokers 
(FS) in the U.S. population. CDC estimates (2010) of relative risks between these populations 
were used for cancers of the esophagus, stomach, bladder, and oral cavity, and for acute 
myeloid leukemia. We also considered other published sources for several tissue sites, which 
are liver, colorectal, and lymphomas (Liang et al., 2009; Sandler et al., 2003; IARC 1986). We 
estimated the fraction of cancers categorized in the ―remainder‖ category based on the number 
of cases reported by Preston et al. (2007) for different cancer types related to smoking including 
pharynx, larynx, and pancreas. Cancer rates reported for the U.S. population are made up of 
populations of S, FS, and NS, with proportions fS, fFS, and fNS, which leads to: 
)()()()()4( 0000 afafafa
NS
TNS
FS
TFS
S
TST    
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The relative risks (RR) of S and FS compared to NS, RRS, and RRFS, respectively, are then 
used to compare rates for NS  to the U.S. average rates, 
 
)(
)(
)()5( 00
NSFSFSSS
TNS
T
ffRRfRR
a
a



  
We used the 2005 U.S. population data from surveillance, epidemiology, and end results (SEER) 
(2006) and the CDC (2008) to represent the average U.S. population, and CDC estimates of 
fractions of populations for S, FS, and NS for males and females above age 40 y. The resulting 
estimates of RR for NS compared to the U.S. population are shown in Table 3. For NS risk 
estimates, we considered their longer lifespan due to their reduced mortality for cancer, and 
circulatory and pulmonary diseases. Age-specific rates for all causes of death for NS were not 
available; instead, we considered the survival probability for the average U.S. population and made 
adjustments for the age- and gender-specific rates for  these diseases (CDC 2008; Malarcher et al., 
2000). Here we modified the survival probability in Eq. (1) to adjust for lower rates for cancers, and 
circulatory and pulmonary diseases that are also linked to tobacco use (CDC 2008). 
Probability of Causation 
The PC or AR is the fraction of the incidence of a disease in a population (exposed and non-
exposed) that is due to radiation exposure. Thus, the PC represents the incidence of a disease 
in the population that would be eliminated if there were no radiation exposure. The PC is 
estimated from Eq. (1) by limiting the upper limit of integration to the date of disease diagnosis, 
aDiag for both the exposed population and the reference population, with the PC defined in terms 
of the conditional tissue specific ERR for each tissue: 
),(1
),(
)6(
Diag
Diag
aTERR
aTERR
PC

  
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1
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),()7(
0
),,(
0




Diag
E
Diag
E
t
E
a
EM
a
a
EIT
a
a
Dazdz
EIT
Diag
tSaadt
etSDaadt
aTERR



 
 
 7 
 
Table 3. Estimates of Relative Risk (RR) for Never-Smokers (NS) compared to Average U.S. Population for 
Several Cancers Related to both Smoking and Radiation Exposure  
 Relative Risk to Never-Smokers  
Males Current smokers Former smokers Never- smokers RR(NS/US) 
Esophagus 6.76 4.46 1 0.27 
Stomach 1.96 1.47 1 0.71 
Bladder 3.27 2.09 1 0.50 
Oral Cavity 10.89 3.4 1 0.23 
Liver 2.25 1.75 1 0.63 
Colorectal 1.19 1.21 1 0.89 
Leukemia 2 1.5 1 0.69 
Remainder 4 2.5 1 0.43 
Lung* 23.26 8.7 1 0.11 
Females Current smokers Former smokers Never- smokers RR(NS/US) 
Esophagus 7.75 2.79 1 0.35 
Stomach 1.36 1.32 1 0.85 
Bladder 2.22 1.89 1 0.65 
Oral Cavity 5.08 2.29 1 0.46 
Liver 2.25 1.75 1 0.67 
Colorectal 1.28 1.23 1 0.88 
Leukemia 2 1.5 1 0.74 
Remainder 4 2.5 1 0.48 
Lung* 12.69 4.53 1 0.23 
*Lung data shown only for comparison, where risk calculations made using age-specific rates described in the text. 
For males, current smokers, former smokers, and never-smokers are estimated at 24, 40, and 36% of the population 
above age 50 y. For females, we use 18, 35, and 47% for these percentages (CDC-MMWR, 2010). 
 
3. Space Radiation and Organ Exposures 
For calculations of space radiation tissue-specific cancer risks, Eq. (2) is used for the cancer 
incidence risk rate with the organ dose equivalent estimated using the high charge and energy 
transport computer code (HZETRN) (Wilson et al., 1994) with quantum multiple scattering 
fragmentation model (QMSFRG) cross-sections and Badhwar-O’Neill GCR environment 
(Cucinotta, et al., 2011). For GCR, the use of risk assessment quantities based on absorbed 
dose is expected to have shortcomings and instead the NASA 2010 derived radiation quality 
descriptors of biological effectiveness based on particle track structure and fluence that were 
then expressed as radiation quality factors (Cucinotta et al., 2011). Here, a cancer risk cross-
section representing the probability per particle is written as: 
])),(1(),([),()8(
0
0 LEZPEZPEZ 



 
with 
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where the three parameters of the model ( /0 , m, and ) based on subjective estimates of 
results from radiobiology experiments. A radiation quality factor function is then found as: 
LET
ZEP
ZEPQNASA
),()/(24.6
)),(1()10(
0 
  
The NASA quality factor depends on both particle charge number, Z and kinetic energy, E and not 
linear energy transfer, linear energy transfer (LET) alone as assumed in the International 
Commission on Radiological Protection (ICRP) definition of quality factors (ICRP 1990; ICRP 
2003; NCRP 2000). Distinct quality factors for estimating solid cancer and leukemia risk are used, 
Qsolid and Qleukemia, respectively. The parameters that enter Eq.’s (8) to (10) have straightforward 
biophysical interpretations: 0  is the maximum value of the cross-section, which is related to 
maximum relative biological effectiveness (RBEmax) for the most biologically effective particle 
types; m is the slope of the cross-section for increasing ionization density;  determines the 
saturation value of the cross-section, where the relative biological effectiveness (RBE) begins to 
decline due to ―overkill‖ effects.  is related to the initial slope of the gamma-ray dose response. 
Only the ratio /0 enters into model calculations, and not the individual values of these 
parameter. For solid cancer risks, radiobiology data is sparse. However, the largest RBE for HZE 
nuclei is in the range from 20 to 50 for solid tumors in rodents, and for chromosomal aberrations 
and mutations in human cells. A lower value is observed for leukemia (Weil et al., 2009). This 
assumes a linear dose response at low particle dose, ignoring non-targeted effects (NTEs) or 
other possible mechanisms that would lead to deviation from linearity at low fluence. Calculations 
with the NASA 2010 model include uncertainty analysis through the use of probability distribution 
functions (PDFs) to represent subjective assessments of ranges for each of the parameters with 
median values shown in Table 4. We also assume a description of ―thindown‖ at low energies, 
where the track width of a particle becomes smaller than the biological target. Here at low 
energies, the Risk cross-section is modified by the factor, PE=1-exp(-E/ETD) to account for 
thindown. The value of ETD=0.2 is based on experimental data for H and He. This factor has a 
very small impact for heavy ions since at low E they make a very small contribution to GCR or  
SPE exposures. The parameter  is assumed to have distinct values for light and heavy ions 
(Table 4).  
Table 4. Cancer Risk Cross-Section or Quality Factor Parameters for Solid Cancer and Leukemia Risks* 
Parameter Solid Cancer Leukemia 
m 3 3 
 550 (1000) 550 (1000) 
0/, m
2 
Gy 7000/6.24 1750/6.24 
ETD 0.2 MeV/u 0.2 MeV/u 
*Values in parenthesis for when distinct values for light ions (Z  4) are to be used.  
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The cancer risk cross-section or related quality factor is expressed in terms of the track 
structure parameter, Xtr= Z
*2/2, using the Barkas form for the effective charge function. The 
quality factor has an additional dependence on LET, which relates the particle track structure to 
the absorbed dose (Cucinotta et al., 2011). Figure 2 compares the NASA quality factor to the 
International Commission on Radiological Protection (ICRP) model used at NASA in the past for 
p, C, Si, and Fe nuclei versus LET illustrating the differences as described. The preferred slope 
on the rising side with increasing ionization density of m=3 is different than the ICRP Q(LET), 
which rises approximately as m=2. For calculations for a specific particle described by Z and E, 
Eq. (2) is replaced by 
 
 ),(),()/()),(1)(,(),(),,()11( 0 EZFEZPEZPZEDaaaaF TTEIETZI     
where I is the inner bracketed terms in Eq. (2) that contains the ERR and EAR functions for 
individual tissues. Using the HZETRN code or similar radiation transport codes, the fluence 
spectra, F(Xtr) can be found by transforming the energy spectra, j(E) for each particle, j of mass 
number and charge number, Aj and Zj respectively as: 
)()()12(
1
E
E
X
XF j
j
tr
tr 

 







  
where we evaluate the Jacobian in Eq. (12) using the Barkas (1963) form for the effective 
charge number given by 
)1()13(
3/2/125* ZeZZ   
The tissue-specific cancer incidence rate for GCR or SPEs can then be written: 






  
j
trtrtrtrjjTIIT XPXFdXXPESEdE )()()/())(1)(()()14( 0    
The first term on the right-hand side of Eq. (14) can be well approximated by the tissue 
averaged absorbed dose times the low LET risk coefficient. This approximation can be shown to 
lead to <10% over-estimation of its true value. However, in REIC calculations the error is even 
smaller because the second term of the right-hand side of Eq.(14) is dominant. We modified the 
HZETRN and BRYNTRN codes to perform the exact calculation; however, for the Monte-Carlo 
uncertainty analysis described below, we use the following form for the radiation cancer rate for 
the mixed particle and energy fields in space: 
  )()()()()'14( 0 trHItrHItrtrLItrLItrIIT XPXFdXXPXFdXDose     
where we distinguish spectra for light ions (Z≤4), FLI from heavy ions, FHI (Z>4). A summation over 
all cancer types is made for the radiation contribution to the survivor function in evaluating tissue 
specific risks, and a further summation over all cancer types to evaluate the overall cancer risk.  
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In organ exposure evaluations, fluence spectra are averaged over each tissue using body 
shielding models. In Figure 3 we show differential REIC spectra versus Xtr at solar minimum 
behind increasing amounts of aluminum shielding for a Mars and an ISS mission. Calculations 
are made with the HZETRN code using the Badhwar and O’Neill GCR model (1992) and 
QMSFRG nuclear cross-section data base (Cucinotta et al., 2007). Results are shown on a 
linear-log plot such that the area under the curve for each decade of Xtr is equally weighted. 
Leukemia risk shows a reduced maximum Q-value compared to solid cancer risks, resulting in 
particles at lower values of Xtr making larger contributions compared to solid cancer risks. 
Figure 3 shows sharp spikes at increasing values of Z2 for each GCR charge group. For 
example, at small values of Xtr we see peaks at 1 and 4, corresponding to protons and He 
nuclei. At large values of Xtr we observe a prominent peak near Z*
2/2 = 676 corresponding to 
relativistic Fe nuclei. These sharp peaks correspond to the contributions from relativistic 
particles, with broader peaks for deep space exposure due to contribution of low- to medium-
energy GCR not present in the ISS orbit due to the Earth’s geomagnetic field.  
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Figure 2. Comparison of LET dependence for H, C, Si, and Fe nuclei in the proposed NASA Quality 
factors for solid cancer and leukemia risk estimation to quality factors from ICRP (ICRP, 1990).  
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Figure 3a. Leukemia and solid cancer risk distribution for 40-y Females versus Z*2/2  on 6-month ISS 
mission at solar minimum with 20 g/cm2 of aluminum shielding.  
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Figure 3b. Leukemia and solid cancer risk distribution for 40-y Females versus Z*2/2 for 30-month 
Mars mission including 18 month surface stay at solar minimum with 20 g/cm2 of aluminum shielding.
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In Figure 4a (Cucinotta et al., 2011), we compare calculations of annual Effective dose in the 
ICRP model to the NASA recommended model for ISS missions at solar minimum and maximum. 
Comparisons for aluminum and polyethylene shielding are shown. Figure 4b shows similar 
comparisons for 1-year in deep space. The ICRP model provides higher estimates at shallow 
shielding depth due largely to its higher estimation of contributions for relativistic particles than the 
NASA model. At deep shielding depths, the NASA model gives higher estimates due to its 
assignment of higher biological effectiveness to low energy proton and helium nuclei produced by 
neutrons and other particles and from atomic slowing-down of primaries. For the various mission 
and shielding scenarios, differences in Effective doses are on the order of 10 to 30%; however, 
the NASA model allows for an improved uncertainty assessment to be made than the ICRP Q 
function whose parameters are difficult to relate to biophysical interpretation. Of note is that 
shielding only provides a minor reduction in GCR organ dose equivalent. Most of the reduction 
occurs in the first 20 g/cm2 of material at solar minimum. The reduced number of low energy 
particles at solar maximum reduces even this benefit from shielding. To significantly reduce GCR 
beyond this initial reduction would require several meters of hydrocarbon shielding. 
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Figure 4a. Comparison of annual Effective dose for males in ISS orbit (51.6 deg x 400 km) versus 
depth of shielding. Values for solar minimum and maximum are shown comparing ICRP model to 
recommended NASA model. 
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4. Uncertainty Analysis 
To propagate uncertainties across multiple contributors, we performed Monte-Carlo simulations 
sampling over subjective PDFs that represent current knowledge of factors that enter into risk 
models (NCRP, 1997; 2006; Cucinotta et al., 2001, 2006; 2011). In a simplified manner, we can 
write a risk equation as a product of several factors including the dose, D, quality factor, Q, a 
low LET risk coefficient normally derived from the data of the atomic-bomb survivors, R0, and 
the dose and dose-rate reduction effectiveness factor, DDREF, that corrects risk data for dose-
rate modifiers. Monte-Carlo uncertainty analysis uses the risk equation, but modified by normal 
deviates that represent subjective weights and ranges of values for various factors that enter 
into a risk calculation. First, we define XR(x) as a random variate that takes on quantiles x1, x2, 
…, xn such that p(xi) =P(X=xi) with the normalization condition  p(xi)=1. C(xi) is defined as the 
cumulative distribution function, C(x), which maps X into the uniform distribution U(0,1) and we 
define the inverse cumulative distribution function C(x)-1 in order to perform the inverse mapping 
of U(0,1) into x: x=C(x)-1. Then we write for a simplified form of the risk equation for a Monte-
Carlo trial, : 











RD
QphysR
x
xxx
DDREF
FLQ
genderageRRisk 0),()15( 0  
where R0 is the low LET risk coefficient per unit dose, the absorbed dose, D is written as the 
product of the particle fluence, F and LET, L, and Q the radiation quality factor. The xR, xphys, xDr, 
and xQ are quantiles that represent the uncertainties in the low LET risk coefficient, the space 
physics models of organ exposures, dose-rate effects, and radiation quality effects, respectively. 
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Figure 4b. Annual GCR Effective doses in deep space versus depth of shielding for males. Values 
for solar minimum and maximum are shown comparing ICRP model to recommended NASA model. 
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Monte-Carlo trials are repeated many times, and resulting values binned to form an overall PDF 
taken into account each of the model uncertainties. In practice, the risk model does not use the 
simple form of Eq.(15). Instead, risk calculations are made using the REIC  described by Eq. 
(1). For the 95% CIs for the %PC, we use the bootstrap method to infer the values from the 
uncertainty analysis for REIC. 
PDF functions describing the uncertainties to the quantiles, x for the various parameters in the 
model are described in Table 5 from the recent report by Cucinotta et al. (2011). Two 
modifications are to introduce tissue-specific statistical uncertainties and to include uncertainties 
in the estimate of RR for NS compared to the U.S. average. The subjective PDFs are then 
employed in the Monte-Carlo calculation to describe a given space radiation scenario as 
described previously (Cucinotta et al., 2001; 2006; 2011). The point estimate for Qmax of 40, 
occurs for the most effective proton energy (~ 0.5 MeV). Values assigned give more weight to 
the animal model solid tumor data and are influenced by fractionation studies that suggest that 
higher RBEs are possible. The resulting PDF has a 95% CI for the maximum value of Q for solid 
cancer as [14, 70], which covers most of the range of values from Fe nuclei tumor induction and 
earlier neutron studies reflective of low energy protons. In Table 4, we use a GM=0.9 for the 
PDF associated with 0 /with the expectation that some tissues would have lower values as 
found for leukemia; however, there is a lack of information to make a more informed choice. In 
an alternative model of the radiation quality uncertainties, we assume that the slope, m is 
correlated with the position of the maximum value of Q as determined by the value of . After 
studying the functional dependence of the parameters of Eq. (10), we find the position of the 
maximum Q is held fixed for differential values of m if we use the constraint: 
)1(
4
)()16( 0


m
m

  
where 0 is the estimated value from Table 4. This alternative uncertainty assessment assumes 
that the kinetic energy for each Z at the maximum of the risk cross-section for cancer induction 
in humans is fairly well described by the existing data. In this approach, uncertainties in the 
maximum Q value, slope of Q with changing Xtr, and kinetic energy at the Q maximum are 
described; however, these values are more constrained compared to the uncertainty analysis 
without this constraint. The alternative uncertainty model was applied using conditional Monte-
Carlo sampling, where a random value of m is selected from its PDF, prior to sampling for the  
value with central estimate defined by Eq.(16). 
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Table 5. Summary of PDF for Uncertainty Components in NASA Model 
Uncertainty Contribution PDF form for Quantile, xj Comment 
Low LET Model: 
Statistical Errors See Table 6 Tissue-specific values used 
Statistical Errors in RR for NS Normal (M=1.0; SD=0.25) Applied to tissues considered in Table 3 
for NS 
Bias in Incidence Data Normal (M=1.0; SD = 0.05) Based on NCRP Report 126 
Dosimetry Errors Log-Normal (GM=0.9, GSD=1.3) Based on Preston et al. (2007); 
UNSCEAR (2008) 
Transfer Model Weights Uniform distribution about preferred 
weight 
Ignored for breast and thyroid cancers 
DDREF Log-Normal (GM=1.0; GSD=1.4) DDREF=1.75; Truncated at 0.75 for  
inverse dose-rate probability <0.05 
Risk Cross Section or Q: 
0/   Log-normal(GM=0.9; GSD=1.4) GM<1 assumes existing data is biased 
to higher values 
 Normal(M=1, SD=0.2) Position of peak estimates suggests 
variation on sensitivity, target size/ 
distributed targets 
m Discrete m=[1.5,2,2.5,3.,3.5,4] with 
weights [.05,.1,.2,.4,.2.,.05] 
Values restricted over (1.5,4) 
Physics Uncertainties: 
F(Z
*2
/
2
) for Z<5 Normal (M=1.05; SD=1/3) HZETRN  does not account for mesons, 
e- and -rays that are low Charge and 
high velocity; may underestimate 
neutron recoils of low charge 
F(Z
*2
/
2
) for Z5 Normal (M=1.0; SD=1/4) HZETRN accurate at high Z 
 
Statistical Uncertainties for Tissue-Specific Estimates 
For estimating the statistical uncertainties for overall cancer risks from radiation, we previously 
used (Cucinotta et al., 2011) the recommendations from NCRP Report 126 (1997) for the 
statistical uncertainty in the total cancer risk derived from cancer mortality data of the LSS 
survivors. However, larger statistical uncertainties occur for tissue-specific risk estimates 
derived from cancer incidence data. The various reports on tissue-specific estimates of cancer 
risks (BEIR VII, 2006; UNSCEAR 2008; Preston et al., 2007) typically combine statistical 
uncertainties with dosimetry or other uncertainties in reporting confidence levels. The 
UNSCEAR report did not report uncertainty ranges for their model EAR and ERR functions, 
which further complicates assessments of tissue-specific statistical uncertainties. The approach 
used here is to introduce subjective PDFs for the tissue-specific statistical uncertainties based 
on the Empirical Bayes (EB) results from Pawel et al. (2009). The important feature of the EB 
approach is to consider the correlation between the standards errors for different tissue sites 
Table 6 shows results from this work. In the last two columns, we show results as the %SD 
relative to the mean estimate, and the subjective values used in our analysis are shown in 
parenthesis. Note that statistical errors for leukemia were not considered by Pawel et al. (2009) 
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and for thyroid and breast cancers, meta-analysis results that included data in addition to the 
Japanese atomic-bomb survivor data was considered as recommended by BEIR VII (2006).  
 
Table 6. Comparison of Maximum Likelihood Estimates (MLE) to Empirical Bayes (EB) Method for Gender 
Adjusted Site-specific ERR from the LSS Study (Pawel et al. 2008), and %SD Estimates and Subjective %SD 
Estimates Used for Model Calculations in Parentheses  
Tissue ERR/Sv Estimate 
MLE          EB 
Standard Error 
 MLE            EB 
%SD EB 
(subjective) 
Stomach 0.32 0.32 0.06 0.06 0.19  (0.2)  
Colon 0.49 0.47 0.11 0.10 0.21 (0.2)  
Liver 0.31 0.32 0.10 0.09 0.28 (0.3)  
Lung 0.70 0.63 0.13 0.11 0.18 (0.2)  
Breast 0.67 0.63 0.10 0.09 0.14 (0.25)  
Prostate 0.18 0.32 0.30 0.19 0.60 (0.6)  
Uterus 0.04 0.05 0.05 0.05 1.0 (1.0)  
Ovary 0.27 0.32 0.19 0.15 0.47 (0.5)  
Bladder 0.84 0.58 0.29 0.18 0.31 (0.3)  
Esophagus 0.63 0.48 0.31 0.19 0.40 (0.4)  
CNS 0.37 0.38 0.17 0.14 0.37 (0.4)  
Thyroid      (0.4)  
Oral Cavity 0.34 0.36 0.15 0.13 0.36 (0.4)  
Remainder* 1.15 0.85 0.19 0.15 0.18 (0.2)  
Leukemia     (0.25)  
*Remainder included different tissues in various reports described in text.  
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5. Results  
Figure 5 illustrates some general characteristics of the %PC for different tissue sites. 
Calculations are shown for an organ dose equivalent of 0.5 Sv to each tissue site for a Female 
NS. Results for leukemia are made at the same the organ dose equivalent as solid cancers; 
however, the NASA model would assign a smaller Q-factor for leukemia resulting in a smaller 
GCR organ dose equivalent for the bone marrow compared to values for solid tissues. The left 
panel of Figure 5 shows calculation for an age of exposure of 40 y and the dependency of the 
%PC with time after exposure. Different trends occur for the tissues shown, which are largely 
determined by the age and time after exposure dependences of the fitted EAR and ERR 
functions, and the age dependence of the background rates for the tissues. Similar trends are 
observed for males (data not shown), The %PC peaks early after exposure for leukemia and 
stomach cancers and rises slowly with time after exposure for breast and lung cancers. There 
are additional uncertainties that are not accounted for with regards to the calculation of %PC 
less than 2 and 5 years after exposure for leukemia and solid cancer, respectively, because 
epidemiology data are often sparse at these times. In addition, heavy ion and neutrons appear 
to cause an earlier induction of cancers than low LET radiation, which is not accounted for in the 
current models of cancer risk (NCRP 2000; NCRP 2006). In the right panel of Figure 5, we 
show calculations of %PC at 20 years post-exposure for different ages of exposure. The %PC 
declines with age at exposure for most but not all tissues because background cancer risks tend 
to increase with age. 
 
  
 
In Tables 7, 8, and 9, we show estimates of tissue-specific %REIC and 95% CL, and point 
estimates and upper 95% CL for %PC for a 1-year NEA mission, a 30-month Mars mission, and 
a 6-month ISS mission, respectively. Calculations for males and females represented by the 
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Figure 5. Calculations of %PC for NS Females for organ dose equivalents of 0.5 Sv. The left panel 
shows results versus time after exposure and the right panel versus age at exposure for disease 
diagnosis at 20 y post-exposure. 
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U.S. average population or a population of NS are shown. For %PC estimates, results are 
shown for disease diagnosis at 20-year post exposure. Results are based on the UNSCEAR 
(2007) models for many tissues with the exceptions for noted before for breast, thyroid, and 
prostate cancer (Cucinotta et al., 2011). Similar results would be found using the BEIR VII 
models; however, the BEIR VII model did not include an age at exposure dependence for rates 
above age 30 y (BEIR VII), and therefore the NASA 2010 model used the UNCEAR models for 
EAR and ERR rate functions. All results are for solar minimum conditions assuming 20 g/cm2 
aluminum shielding. However, Figure 4 shows that larger amounts of shielding (up to 120 
g/cm2) would not change the results significantly, and a modest improvement is made by using 
polyethylene or water equivalent shielding compared to aluminum. Any time spent on 
extravehicular activities (EVAs) would marginally increase these results for solar minimum 
conditions. At solar maximum, the uncertainty in SPE environments is an important 
consideration (Kim et al., 2009). SPE’s uncertainties related to time of occurrence, total fluence, 
and energy spectra play a much larger role for EVAs and will be considered elsewhere. 
The estimates of PC for stomach and leukemia cancers show the largest association with GCR 
exposures followed by colon, liver, bladder, and lung cancers. An important gender dependence 
occurs between values for several tissues. For a Mars mission, estimates of the %PC at the 
95% confidence level would suggest a large proportion of cancers that would be observed in 
astronauts would be either caused or moved forward in time by radiation exposure. In contrast, 
a single ISS mission at solar minimum does not lead to %PC estimates above 50% for any 
tissue even at the 95% CL. However, for an individual making two or more ISS missions, PC 
values for leukemia and stomach cancers would likely exceed 50% at the 95% CL, and lung 
cancer PC estimates for NS would approach 50% at the 95% CL. The results shown in Table 8 
are for the conjunction-type Mars mission. In comparison, the shorter opposition class missions 
have  more time in deep space than the conjunction class missions. Thus, the conjunction class 
missions, which have long stays on the Mars surface, benefit from the 2 shielding provided by 
the solid body of Mars and its atmospheric shielding. The net effect is for a decreased risk for 
conjunction class missions compared to opposition class missions at solar minimum. The same 
is true at solar maximum because the risk of a high SPE exposure on the Mars surface is 
greatly reduced compared to the SPE risk in deep space.  
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Table  7a. Lifetime %REIC and 95% CI, and  %PC for 60 y Females Following 1-year NEA Mission at 
age 40 y. Calculations Assume 20 g/cm
2
 Aluminum Shielding for Solar Minimum Conditions. 
Tissue %REIC %PC 
(95% CL) 
%REIC %PC 
(95% CL) 
 U.S. Ave. Females NS Females 
Stomach 0.331 [0.091,  1.31] 54.0 (82.2) 0.347 [0.095,  1.39] 57.6 (84.5) 
Colon 0.461 [0.135,  1.79] 21.1 (51.0) 0.439 [0.128,  1.71] 21.2 (51.1) 
Liver 0.117 [0.026,  0.459] 27.7 (60.0) 0.117 [0.026,  0.466] 34.6 (67.9) 
Lung 2.06   [0.602,  8.02] 21.6 (51.7) 0.815 [0.238,  3.20] 41.2 (73.3) 
Breast 0.737 [0.215,  2.88]  5.98 (19.9) 0.779 [0.228,  3.00]  5.99 (20.1) 
Uterus 0.133 [0.0,  0.791]  5.73 (26.6) 0.140 [0.0,  0.835]  5.74 (26.6) 
Ovary 0.156 [0.0,   0.693] 11.7 (37.1) 0.165 [0.0,  0.742] 11.7 (37.3) 
Bladder 0.331 [0.079,  1.29] 19.0 (47.6) 0.299 [0.071,  1.18] 22.1 (53.0) 
Esophagus 0.034 [0.006,  0.141] 15.7 (43.5) 0.016 [0.003,  0.069] 23.8 (56.7) 
Brain-CNS 0.044 [0.007,  0.183] 12.1 (36.5) 0.046 [0.007,  0.194] 12.1 (36.7) 
Thyroid 0.123 [0.021,  0.516] 12.1 (36.6) 0.126 [0.021,  0.531] 12.1 (36.7) 
Oral Cavity 0.022 [0.004,  0.090]  5.70 (20.1) 0.022 [0.004,  0.094] 11.6 (35.5) 
Remainder 0.479 [0.132,  1.90] - 0.242 [0.066,  0.958] - 
Leukemia 0.392 [0.142,  1.38] 57.3 (82.5) 0.344 [0.125,  1.22] 62.2 (85.5) 
Total  5.71   [1.77, 20.8] - 4.11  [1.35, 15.1] - 
 
Table  7b. Lifetime %REIC and 95% CI, and  %PC for 60 y Males Following 1-year NEA Mission at age 
40 y. Calculations Assume 20 g/cm
2
 Aluminum Shielding for Solar Minimum Conditions. 
Tissue %REIC %PC 
(95% CL) 
%REIC %PC 
(95% CL) 
 U.S. Ave. Males NS Males 
Stomach 0.316 [0.087,  1.23] 38.7 (71.0) 0.329 [0.085,  1.29] 45.8 (76.7) 
Colon 0.491 [0.135,  1.89] 20.8 (50.3) 0.485 [0.133,  1.87] 20.8 (50.3) 
Liver 0.141 [0.031,  0.549] 12.3 (35.3) 0.131 [0.029,  0.513] 14.9 (40.8) 
Lung 0.750 [0.206,  2.88]  6.87 (22.1) 0.386 [0.106,  1.50] 30.1 (62.6) 
Prostate 0.289 [0.0,  1.38]  1.94 (8.63) 0.319 [0.0,  1.53]  1.94 (8.66) 
Bladder 0.677 [0.150,  2.61] 14.6 (39.7) 0.466 [0.103,  1.82] 16.7 (43.9) 
Esophagus 0.109 [0.016,  0.45] 11.4 (34.7) 0.037 [0.006,  0.151] 14.0 (40.1) 
Brain-CNS 0.045 [0.007,  0.186]  9.40 (30.0) 0.049 [0.007,  0.201]  9.41 (30.1) 
Thyroid 0.024 [0.004,  0.1]  6.26 (21.5) 0.026 [0.004,  0.107]  6.27 (21.5) 
Oral Cavity 0.019 [0.004,  0.076]  1.83 (6.94) 0.020 [0.004,  0.082]  7.32 (24.6) 
Remainder 0.419 [0.108,  1.65]  - 0.198 [0.051,  0.771]  - 
Leukemia 0.612 [0.211,  2.13] 59.9 (83.4) 0.537 [0.186,  1.89] 66.1 (87.3) 
Total  4.00  [1.31, 14.6] - 3.07 [1.01, 11.2] - 
 20 
 
Table  8a. Lifetime %REIC and 95% CI, and  %PC for 60 y Females Following 30-month Mars Mission at 
age 40 y. Calculations Assume 20 g/cm
2
 Aluminum Shielding for Solar Minimum Conditions. 
Tissue %REIC %PC 
(95% CL) 
%REIC %PC 
(95% CL) 
 U.S. Ave. Females NS Females 
Stomach 0.556 [0.153,  2.15] 66.8 (88.6) 0.585 [0.161,  2.31] 70.0 (90.2) 
Colon 0.762 [0.223,  2.91] 31.3 (63.5) 0.728 [0.213,  2.82] 31.4 (63.9) 
Liver 0.198 [0.044,  0.769] 39.7 (71.9) 0.198 [0.044,  0.792] 47.7 (78.5) 
Lung 3.46 [1.010, 12.5] 31.9 (63.7) 1.37   [0.401,  5.22] 54.3 (81.9) 
Breast 1.18 [0.345,  4.44]  9.65 (28.7) 1.25   [0.366,  4.83]  9.67 (29.2) 
Uterus 0.223 [0.0,  1.32]  9.43 (38.1) 0.235 [0.0,  1.39]  9.45 (38.2) 
Ovary 0.261 [0.0,  1.13] 18.5 (49.7) 0.278 [0.0,  1.22] 18.5 (49.9) 
Bladder 0.559 [0.134,  2.07] 28.7 (59.8) 0.508 [0.122,  1.93] 32.8 (65.0) 
Esophagus 0.057 [0.010,  0.234] 24.1 (56.4) 0.028 [0.005,  0.113] 34.8 (68.6) 
Brain-CNS 0.072 [0.012,  0.294] 18.8 (48.6) 0.076 [0.013,  0.314] 18.9 (49.0) 
Thyroid 0.187 [0.032,  0.788] 18.7 (49.1) 0.194 [0.033,  0.818] 18.7 (49.3) 
Oral Cavity 0.035 [0.007,  0.143]  9.14 (29.0) 0.037 [0.007,  0.152] 17.9 (47.5) 
Remainder 0.777 [0.213,  2.95] - 0.394 [0.108,  1.52] - 
Leukemia 0.651 [0.236,  2.24] 69.5 (88.7) 0.573 [0.208,  2.0] 73.6 (90.7) 
Total  9.41 [3.09, 33.1] - 6.78 [2.22, 24.3] - 
 
Table  8b. Lifetime %REIC and 95% CI, and  %PC for 60 y Males Following 30-month Mars Mission at age 
40 y. Calculations Assume 20 g/cm
2
 Aluminum Shielding for Solar Minimum Conditions. 
Tissue %REIC %PC 
(95% CL) 
%REIC %PC 
(95% CL) 
 U.S. Ave. Males NS Males 
Stomach 0.530 [0.145,  2.05] 52.1 (80.8) 0.555 [0.152,  2.18] 59.2 (85.1) 
Colon 0.816 [0.238,  3.14] 30.9 (63.3) 0.807 [0.221,  3.11] 31.0 (63.3) 
Liver 0.237 [0.053,  0.918] 19.4 (48.2) 0.221 [0.049,  0.87] 23.1 (54.3) 
Lung 1.26   [0.369,  4.71] 11.2 (32.0) 0.652 [0.179,  2.47] 42.4 (73.6) 
Prostate 0.483 [0.0,  2.27]  3.25 (13.6) 0.535 [0.0,  2.53]  3.25 (13.7) 
Bladder 1.15   [0.254,  4.34] 22.7 (52.7) 0.792 [0.175,  3.01] 25.6 (56.7) 
Esophagus 0.184 [0.031,  0.749] 18.1 (47.3) 0.062 [0.009,  0.252] 21.8 (53.1) 
Brain-CNS 0.073 [0.012,  0.298] 14.9 (41.6) 0.080 [0.013,  0.326] 14.9 (41.8) 
Thyroid 0.038 [0.006,  0.157] 10.2 (32.0) 0.041 [0.007,  0.170] 10.2 (32.0) 
Oral Cavity 0.031 [0.006,  0.122]  3.03 (11.1) 0.032 [0.006,  0.132] 11.8 (35.3) 
Remainder 0.683 [0.188,  2.60] - 0.325 [0.089,  1.23] - 
Leukemia 1.02 [0.351,  3.50] 71.8 (89.8) 0.891 [0.308,  3.09] 76.9 (92.0) 
Total  6.70  [2.20, 23.6] - 5.15  [1.69, 18.3] - 
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Table 9a.  Lifetime %REIC and 95% CI, and %PC for 60 y Females Following ISS Mission at age 40 y.  
Calculations Assume 20 g/cm
2
 Aluminum Shielding for Solar Minimum Conditions with Mission Length of 180 d. 
Tissue %REIC %PC 
(95% CL) 
%REIC %PC 
(95% CL) 
 U.S. Ave. Females NS Females 
Stomach 0.031 [0.008,  0.126]  9.75 (30.4) 0.032 [0.008,  0.131] 11.1 (33.7) 
Colon 0.043 [0.012,  0.172]  2.38 (8.88) 0.041 [0.011,  0.161]  2.39 (8.82) 
Liver 0.011 [0.002,  0.045]  3.41 (12.6) 0.011 [0.002,  0.044]  4.67 (16.6) 
Lung 0.192 [0.053,  0.765]  2.45 (9.10) 0.075 [0.021,  0.304]  5.99 (20.4) 
Breast 0.069 [0.019,  0.276]  0.57 (2.24) 0.072 [0.020,  0.291]  0.57 (2.26) 
Uterus 0.012 [0.0,  0.075]  0.56 (3.26) 0.013 [0.0,  0.078]  0.56 (3.26) 
Ovary 0.015 [0.0,  0.066]  1.20 (5.25) 0.015 [0.0,  0.070]  1.20 (5.27) 
Bladder 0.031 [0.007,  0.126]  2.12 (8.02) 0.028 [0.006,  0.113]  2.56 (9.57) 
Esophagus 0.003 [0.001,  0.014]  1.68 (6.79) 0.002 [0.000,  0.006]  2.78 (10.8) 
Brain-CNS 0.004 [0.001,  0.017]  1.22 (5.01) 0.004 [0.001,  0.018]  1.22 (5.01) 
Thyroid 0.011 [0.002,  0.048]  1.21 (4.95) 0.012 [0.002,  0.049]  1.21 (4.93) 
Oral Cavity 0.002 [0.001,  0.009]  0.59 (2.21) 0.002 [0.001,  0.009]  1.21 (4.68) 
Remainder 0.045 [0.012,  0.180]  - 0.022 [0.006,  0.091] - 
Leukemia 0.036 [0.012,  0.129] 10.9 (30.4) 0.031 [0.011,  0.113] 13.0 (35.0) 
Total  0.529 [0.164,  1.99] - 0.379 [0.117,  1.43] - 
 
Table 9b.  Lifetime %REIC and 95% CI, and %PC for 60 y Males Following ISS Mission at age 40 y.  
Calculations Assume 20 g/cm
2
 Aluminum Shielding for Solar Minimum Conditions with Mission Length of 180 d. 
Tissue %REIC %PC 
(95% CL) 
%REIC %PC 
(95% CL) 
 U.S. Ave. Males NS Males 
Stomach 0.029 [0.008,  0.117]  5.52 (18.9) 0.031 [0.008,  0.122]  7.25 (23.7) 
Colon 0.045 [0.012,  0.179]  2.34 (8.64) 0.045 [0.012,  0.174]  2.35 (8.54) 
Liver 0.013 [0.003,  0.053]  1.28 (4.91) 0.012 [0.003,  0.049]  1.59 (6.08) 
Lung 0.070 [0.019,  0.274]  0.67 (2.59) 0.036 [0.010,  0.142]  3.80 (13.5) 
Prostate 0.027 [0.0,  0.130]  0.18 (0.87) 0.029 [0.0,  0.143]  0.18 (0.87) 
Bladder 0.064 [0.014,  0.252]  1.56 (5.91) 0.044 [0.010,  0.173]  1.82 (6.87) 
Esophagus 0.010 [0.002,  0.043]  1.18 (4.77) 0.003 [0.001,  0.014]  1.47 (5.87) 
Brain-CNS 0.004 [0.001,  0.017]  0.93 (3.79) 0.004 [0.001,  0.019]  0.93 (3.78) 
Thyroid 0.002 [0.000,  0.010]  0.61 (2.48) 0.002 [0.000,  0.010]  0.61 (2.46) 
Oral Cavity 0.003 [0.001,  0.008]  0.23 (0.71) 0.002 [0.001,  0.008]  0.77 (2.92) 
Remainder 0.039 [0.010,  0.155]  - 0.018 [0.005,  0.073] - 
Leukemia 0.056 [0.019,  0.198] 12.0 (32.7) 0.049 [0.017,  0.175] 15.1 (38.9) 
Total  0.372 [0.122,  1.38] - 0.284 [0.093,  1.05] - 
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6. Discussion and Conclusions 
The results reported here suggest that a large portion of cancers that would be observed in 
crews after long-term missions to NEAs or Mars could be attributed to GCR exposure. However, 
it should be noted that current estimates of 95% confidence levels for the 3% REID limit would 
restrict deep space missions to 4 to 8 months depending on age, gender, and prior exposures. 
For example, 40-y NS males and females with small prior exposures would be limited to 7 and 8 
months, respectively, with heavy shielding at solar minimum. Thus, the %PC at the maximum 
allowed mission length would be reduced by about 30% from the values in Table 7 for an NEA 
mission near solar minimum. In contrast, PC estimates for ISS missions are not estimated to be 
significant due to the smaller mission length and because of the larger fraction of crew 
exposures from the higher energy GCR and trapped protons, which have smaller quality factors 
and uncertainties compared to the full GCR spectrum in deep space. The deep space GCR 
environment contains a larger fraction of particles with kinetics energies below 1000 MeV/u than 
the ISS orbit, and HZE nuclei at these energies are expected to have the maximum biological 
effectiveness (Cucinotta et al., 2011). 
The majority of astronauts are surely classified as ―healthy workers‖ based on established 
evidence of optimal nutrition, exercise, medical care, and NS status, thereby reducing cancer 
risks. This leads to the paradoxical result that radiation cancer risks are estimated to be 
significantly reduced for NS and healthy workers such as astronauts compared to the average 
U.S. population, while probability of causation estimates for several cancer types are increased. 
Furthermore, the use of an NS population to represent astronauts may lead to an under-
estimation of PCs, which is suggested by Kaplan-Meir survival analysis and SMR results of 
Figure 1 and Table 1. These results suggest that adjustment for smoking effects does not 
account for the entire increase in longevity or reduced SMR found for astronauts at this time. 
Because multiplicative risk transfer models are most often used for solid cancer risk estimates, 
further research on categorizing healthy worker effects could play a significant role in both 
radiation risk and probability of causation estimates. In fact, the level of risk reduction predicted 
for NS compared to the average U.S. population is greater than the organ dose equivalent 
reduction that would be provided to crew by more than 1 meter of polyethylene or water 
shielding. This suggests that research into healthy workers effects could lead to substantial cost 
reduction for a NEA or Mars missions, because of the very large cost to launch shielding into 
deep space in comparison to the costs of research efforts. Research into uncertainty reduction 
remains the principal approach to improvements in this and other areas of radiation risk 
estimation and mitigation.  
Probability of causation provides an indicator of possible association; however, clearly other 
information should be collected to ascertain potential causal relationships. A %PC above 50% 
either at the point estimate or at the 95% or even 99% CL has been used in compensation of 
workers including military and nuclear reactor workers (DHHS 2002; NIH 2003; Leigh and 
Wakeford, 2001). Family history and an individual’s possible exposure to other carcinogens 
should be considered in an assessment of possible causality. The use of family history data 
should consider the possibility that genetic predisposition of specific cancer types (NCRP 2011) 
may also confer increased radiation sensitivity. Other factors to be considered include smoking 
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history, which effects lung, esophagus, oral, bladder, and several other cancers, and reproductive 
history, which can impact the risk of breast and other cancers in women (NIH 2003). 
Stomach cancer and leukemia have the largest PC values, and astronauts that participate in 
two or more ISS missions could reach a significant PC for these tumor types. Our estimates 
used the NASA 2010 model, which assigns a smaller quality factors for leukemia compared to 
solid cancers. An even higher PC for leukemia would be predicted if the ICRP-60 quality factors 
were assumed. For stomach cancer risk estimates, we used the BEIR VII (2006) 
recommendation for tissue weighting factors for the relative contributions for multiplicative and 
additive risk transfer for stomach cancer. It is known that the use of the additive risk transfer 
model based on the Japanese A-bomb survivor data leads to a much higher risk estimate for 
stomach cancers in the U.S. population (NCRP, 1997) than the multiplicative transfer model. 
Studies of solid tumor risks across different strains of mice are supportive of multiplicative risk 
transfer (Storer et al., 1988). The BEIR VII report (2006) recommended higher transfer weights 
for multiplicative risk transfer than earlier reports. This is a good example of the importance of 
improving the understanding of the extrapolation of radiation data between populations and from 
experimental results to humans because the choice of transfer models can widely change REIC 
and PC estimates for exploration missions.  
The discovery of biomarkers of radiation-induced cancers is an outstanding problem. Studies of 
cytogenetic signatures of thyroid cancer were reported (Nikiforov et al., 1997), but very little 
information is available for other tissues. In recent years, molecular signatures of radiation 
causality have been investigated, including transcriptome analysis (Detours et al., 2005; Port et 
al., 2007; Ugolin et al., 2011), but have led to conflicting results. For space radiation exposures, 
research into biomarkers of causality is more challenging because of the types of radiation in 
space and lack of any human data. Approaches based on experimentally produced tumors in 
animal models should be considered, and will require improved understanding of methods of 
extrapolation to humans.  
In future work, the approach used here will be extended to include other cancer types including 
non-melanoma skin cancer (Kim et al., 2006), bone cancer, and components of the remainder 
term, which includes renal, gallbladder, pancreatic, larynx, and several other cancers. Also, 
information of the components of leukemia and lung cancer risks should be considered and may 
allow for PC estimates based on distinct histological types for these tumors. In addition, more 
extensive Monte-Carlo evaluations should be made to report 99% CIs, which are used in 
screening terrestrial radiation workers for possible compensation considerations. Reduction in 
the uncertainties in projecting space radiation risks through further cost-effective research will 
have the largest impact on these challenges to NASA and space exploration. Finally, it should 
be noted that NASA policy to limit REID to 3% at the 95% CL strongly overlaps with a goal of 
ensuring estimates of the PC for most cancer types do not reach a level of significance.  
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